

CANCER PREVENTION RESEARCH

TABLE OF CONTENTS

SPOTLIGHT

- 803** **How Does Obesity Drive Human Carcinogenesis? Challenges in Dissecting the Mechanisms of Adipose-Epithelial Signaling**
Justin Colacino, Zora Djuric, and Dean E. Brenner
See related article, p. 817

COMMENTARY

- 807** **Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative**
V. Craig Jordan


RESEARCH ARTICLES

- 817** **Multi-omics Analysis Reveals Adipose-tumor Crosstalk in Patients with Colorectal Cancer**
Andreana N. Holowatyj, Mariam Haffa, Tengda Lin, Dominique Scherer, Biljana Gigic, Jennifer Ose, Christy A. Warby, Caroline Himbert, Clare Abbenhardt-Martin, David Achaintre, Juergen Boehm, Kenneth M. Boucher, Audrey Gicquiau, Andrea Gsur, Nina Habermann, Esther Herpel, Hans-Ulrich Kauczor, Pekka Keski-Rahkonen, Matthias Kloor, Magnus von Knebel-Doeberitz, Dieuwertje E. Kok, Johanna Nattenmüller, Peter Schirmacher, Martin Schneider, Petra Schrotz-King, Thomas Simon, Per M. Ueland, Richard Viskochil, Matty P. Weijnenberg, Augustin Scalbert, Alexis Ulrich, Laura W. Bowers, Stephen D. Hursting, and Cornelia M. Ulrich
See spotlight article, p. 803
- 829** **A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers**
Philip E. Castle, Amanda J. Pierz, Rachael Adcock, Shagufta Aslam, Partha S. Basu, Jerome L. Belinson, Jack Cuzick, Mariam El-Zein, Catterina Ferreccio, Cynthia Firnhaber, Eduardo L. Franco, Patti E. Gravitt, Sandra D. Isidean, John Lin, Salaheddin M. Mahmud, Joseph Monsonego, Richard Muwonge, Samuel Ratnam, Mahboobeh Safaeian, Mark Schiffman, Jennifer S. Smith, Avril Swarts, Thomas C. Wright, Vanessa Van De Wyngard, and Long Fu Xi
- 841** **Inflammatory and Insulinemic Dietary Patterns: Influence on Circulating Biomarkers and Prostate Cancer Risk**
Desmond Aroke, Edmund Folefac, Ni Shi, Qi Jin, Steven K. Clinton, and Fred K. Tabung
- 853** **Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial**
Lauren M. Hurwitz, Ibrahim Kulac, Berrak Gumuskaya, Javier A. Baena Del Valle, Ines Benedetti, Fan Pan, Jun O. Liu, Michael T. Marrone, Kathryn B. Arnold, Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, Ian M. Thompson, Charles G. Drake, William B. Isaacs, William G. Nelson, Angelo M. De Marzo, and Elizabeth A. Platz
- 863** **Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk**
Elizabeth L. Barry, Veronika Fedirko, Karan Uppal, Chunyu Ma, Ken Liu, Leila A. Mott, Janet L. Peacock, Michael N. Passarelli, John A. Baron, and Dean P. Jones
- 877** **Effect of Low-dose and Standard-dose Aspirin on PGE₂ Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial**
David A. Drew, Madeline M. Schuck, Marina V. Magicheva-Gupta, Kathleen O. Stewart, Katherine K. Gilpin, Patrick Miller, Melanie P. Parziale, Emily N. Pond, Oliver Takacsi-Nagy, Dylan C. Zerjav, Samantha M. Chin, Jennifer Mackinnon Krems, Dana Meixell, Amit D. Joshi, Wenjie Ma, Francis P. Colizzo, Peter J. Carolan, Norman S. Nishioka, Kyle Staller, James M. Richter, Hamed Khalili, Manish K. Gala, John J. Garber, Daniel C. Chung, Joseph C. Yarz, Lawrence Zukerberg, Giovanna Petrucci, Bianca Rocca, Carlo Patrono, Ginger L. Milne, Molin Wang, and Andrew T. Chan

TABLE OF CONTENTS

ABOUT THE COVER

Three studies in this issue investigate biomarker modification by aspirin, use of which has been shown to be effective for preventing some cancers. First, in a study beginning on page 853, Hurwitz and colleagues found that aspirin users were more likely to have low levels of FoxP3, a T regulatory cell marker, suggesting that aspirin may alter the immune milieu of the prostate and lower risk of advanced/fatal prostate cancer. Second, in a study beginning on page 863, Barry and colleagues discovered three aspirin-associated metabolic features that might contribute to lower risk of adenoma and colorectal cancer. Last, in a randomized trial beginning on page 877, Drew and colleagues found that aspirin significantly reduced elevated levels of PGE-M in those at increased colorectal cancer risk to levels consistent with lower risk for recurrent neoplasia, suggesting that PGE-M could be used as a precision chemoprevention biomarker. Results from these studies provide evidence to further understand the cancer preventive function of aspirin and to develop precision prevention approaches. The cover image depicts aspirin pills and structure.



Cancer Prevention Research

13 (10)

Cancer Prev Res 2020;13:803-888.

Updated version Access the most recent version of this article at:
<http://cancerpreventionresearch.aacrjournals.org/content/13/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/13/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.